RankMHC: Learning to Rank Class-I Peptide-MHC Structural Models
Journal of Chemical Information and Modeling · 09.12.2024 · 64 (23) · 8729-8742
DOI: 10.1021/acs.jcim.4c01278 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Chemical Information and Modeling, online erschienen am 18.11.2024. Verfasst von Romanos Fasoulis und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Computer Science, Rice University, Houston, Texas 77005, United States. Hauptthemen laut MEDLINE: Peptides, Histocompatibility Antigens Class I. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 98 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS, National Cancer Institute, Rice University.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Computer Science, Rice University, Houston, Texas 77005, United States.
- Institute of Informatics and Telecommunications, NCSR Demokritos, Athens 15341, Greece.
- Ken Kennedy Institute, Rice University, Houston, Texas 77005, United States.
ORCID-Profile: Romanos Fasoulis, Lydia E Kavraki
Förderung
- NCI NIH HHS
- National Cancer Institute
- Rice University
Zitieren
APA
Fasoulis, R., Paliouras, G., & Kavraki, L. E. (2024). RankMHC: Learning to Rank Class-I Peptide-MHC Structural Models. Journal of Chemical Information and Modeling, 64(23), 8729-8742. https://doi.org/10.1021/acs.jcim.4c01278
Vancouver
Fasoulis R, Paliouras G, Kavraki LE. RankMHC: Learning to Rank Class-I Peptide-MHC Structural Models. Journal of Chemical Information and Modeling. 2024;64(23):8729-8742. doi:10.1021/acs.jcim.4c01278
BibTeX
@article{Fasoulis2024,
author = {Fasoulis, Romanos and Paliouras, Georgios and Kavraki, Lydia E},
title = {RankMHC: Learning to Rank Class-I Peptide-MHC Structural Models},
journal = {Journal of Chemical Information and Modeling},
year = {2024},
volume = {64},
number = {23},
pages = {8729--8742},
doi = {10.1021/acs.jcim.4c01278}
}
EUVIMED